Reported Earlier, Bristol Myers Reports Long-Term Camzyos Data Supporting Continued Use In Obstructive HCM
Bristol Myers Squibb (NYSE:BMY) today presented results from the EXPLORER-LTE cohort of the MAVA-LTE study (NCT03723655) in a late-breaker presentation at the European Society of Cardiology (ESC) Congress 2026 in
Bristol Myers showed that its heart medicine Camzyos still works well over a long time for a serious heart condition. When a company proves its medicine keeps helping people safely, that's a positive sign people might keep using it.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.